Systemic therapy in metastatic renal cell carcinoma

World Journal of Urology

Volumn 35, Issue 2, 2017, Pages 179-188

  Bedke, Jens ^a   Gauler, Thomas ^b   Grünwald, Viktor ^c   Hegele, Axel ^d   Herrmann, Edwin ^e   Hinz, Stefan ^f   Janssen, Jan ^g   Schmitz, Stephan ^h   Schostak, Martin ⁱ   Tesch, Hans ^j   Zastrow, Stefan ^k   Miller, Kurt ^f  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g Onkologie Westerstede   (Germany)

^h Gemeinschaftspraxis für Hämatologie und Onkologie Köln   (Germany)

ⁱ OTTO VON GUERICKE UNIVERSITY   (Germany)

^j Bethanien Krankenhaus Frankfurt   (Germany)

^k DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

Checkpoint inhibitor; Renal cell carcinoma; Sequence; Systemic treatment; Targeted therapy; Tyrosine kinase inhibitor mTOR inhibition

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CARBANILAMIDE DERIVATIVE; EVEROLIMUS; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE; NIVOLUMAB; PAZOPANIB; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SULFONAMIDE; SUNITINIB; TEMSIROLIMUS;

ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; DECISION TREE; HUMAN;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DECISION TREES; EVEROLIMUS; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIMIDINES; PYRROLES; SIROLIMUS; SULFONAMIDES;

EID: 84973645179     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-016-1868-5     Document Type: Review

References (43)

1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924. doi:10.1016/j.eururo.2015.01.005
2. Lipworth L, Tarone RE, Lund L, McLaughlin JK (2009) Epidemiologic characteristics and risk factors for renal cell cancer. Clin Epidemiol 1:33–43
3. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373(9669):1119–1132. doi:10.1016/S0140-6736(09)60229-4
4. Catto JW, Shariat SF (2013) The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor’s biology. Eur Urol 63(5):855–857. doi:10.1016/j.eururo.2012.09.049 (discussion 857–858)
5. Rohan SM, Xiao Y, Liang Y, Dudas ME, Al-Ahmadie HA, Fine SW, Gopalan A, Reuter VE, Rosenblum MK, Russo P, Tickoo SK (2011) Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Modern Pathol 24(9):1207–1220. doi:10.1038/modpathol.2011.80
6. Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499(7456):43–49. doi:10.1038/nature12222
7. Onkologie L (2015) Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms, Langversion 1.0, 2015, AWMF Registernummer: 043/017OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html (Zugriff am: 25.04.2016)
8. Patard JJ, Rioux-Leclercq N, Fergelot P (2006) Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49(4):633–643
9. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434. doi:10.1056/NEJMoa021491
10. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 12(24):7215–7220
11. OCEBM Levels of Evidence Working Group*. “The Oxford Levels of Evidence 2”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653
12. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67
13. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY (2015) The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 16(3):293–300. doi:10.1016/S1470-2045(14)71222-7
14. Sun M, Larcher A, Karakiewicz P (2014) Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int J Nephrol Renovasc Dis 7:401–407
15. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY (2013) Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119(16):2999–3006. doi:10.1002/cncr.28151
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi:10.1200/jco.2008.20.1293
18. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068. doi:10.1200/jco.2009.23.9764
19. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID (2013) A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 49(6):1287–1296
20. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. doi:10.1056/NEJMoa1303989
21. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769–1770. doi:10.1056/NEJMc1400731
22. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111. doi:10.1016/S0140-6736(07)61904-7
23. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144–2150. doi:10.1200/JCO.2009.26.7849
24. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271–2281. doi:10.1056/NEJMoa066838
25. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456. doi:10.1016/s0140-6736(08)61039-9
26. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256–4265. doi:10.1002/cncr.25219
27. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939. doi:10.1016/S0140-6736(11)61613-9
28. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552–562. doi:10.1016/S1470-2045(13)70093-7
29. Sharma P, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Xu LA, Waxman IM, Motzer RJ (2015) CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). Paper presented at the European Cancer Congress (abstr 3LBA)
30. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu L-A, Waxman IM, Sharma P (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813
31. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1814–1823. doi:10.1056/NEJMoa1510016
32. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, Kollmannsberger C, Rha SY, Bjarnason GA, Melichar B, De Giorgi U, Grunwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15(3):286–296. doi:10.1016/S1470-2045(14)70030-0
33. Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48(3):333–339. doi:10.1016/j.ejca.2011.11.027
34. Eder E, Müller L, Hübner A, Koska M, Marschner N, Goebbel PJ (2014) Behandlungsrealiät von Patienten mit metastasiertem Nierenzellkarzinom in Deutschland - Daten aus dem RCC-Register. Paper presented at the Gemeinsame Tagung BUV/OEGU (abstr FV17)
35. Knox J, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R (2015) Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC). J Clin Oncol 33 (suppl; abstr 4554)
36. Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmuller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Florcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS (2015) SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur Urol 68(5):837–847. doi:10.1016/j.eururo.2015.04.017
37. Michel MS, Vervenne W, de Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler MD, Pahernik S, Los M, Schenck M, Flörcken A, Van Arckel C, Hauswald K, Indorf M, Gottstein D, Eichelberg C (2015) SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). J Clin Oncol 32 (suppl 4; abstr 393)
38. Procopio G, Bellmunt J, Dutcher J, Bracarda S, Knox J, Brueckner A, Molnar I, Escudier B, Hutson TE (2013) Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis. Br J Cancer 108(2):311–318. doi:10.1038/bjc.2012.543
39. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ (2014) Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32(25):2765–2772. doi:10.1200/JCO.2013.54.6911
40. Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanovic S, Behnes CL, Stenzl A (2014) Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 32(1):31–38. doi:10.1007/s00345-013-1033-3
41. Rini B, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb S, Bedke J, Ludwig J, Mauer D, Mendrzyk R, Mahr A, Fritsche J, Weinschenk T, Singh H, Kirner A, Reinhardt C, Eisen T (2015) Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. Paper presented at the European Cancer Conference (abstr 17LBA)
42. Bedke J, Kruck S, Gakis G, Stenzl A, Goebell PJ (2015) Checkpoint modulation: a new way to direct the immune system against renal cell carcinoma. Hum Vaccines Immunother 11(5):1201–1208. doi:10.1080/21645515.2015.1016657
43. Powles T, Staehler M, Ljungberg B, Bensalah K, Canfield SE, Dabestani S, Giles R, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Volpe A, Bex A (2016) Updated EAU guidelines for clear cell renal cancer patients who fail vegf targeted therapy. Eur Urol 69(1):4–6. doi:10.1016/j.eururo.2015.10.017